Monday 20 th July 2009 Parkinson’s Summerschool A Personal Perspective On Parkinson’s Tom Isaacs Co-Founder – Cure Parkinson’s Trust Board Member – European.

Slides:



Advertisements
Similar presentations
Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
Advertisements

Linda Pituch, Patient Services Manager, Parkinson’s Disease Foundation
Parkinson’s Finding the cure Presentation
Parkinson's Disease Animal Models and Possible Treatments.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
An Overview of Conventional and Experimental Treatments
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Famous Faces of Parkinson Michael J. Fox Muhammad Ali Katharine Hepburn Pope John Paul II Johnny Cash Mao Tse Tung.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Harald Bjorndalen Adapted from lecture by Dr Zoe Campbell (Medical SpR)
Electrical stimulation of the brain: Deep Brain Stimulation (DBS)
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Is it a neurodegenerative brain disorder that progresses slowly in most people.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Deep Brain Stimulation For parkinson’s disease
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Parkinson’s Disease By Devin Cornford
Parkinson ’ s A Review and Practical Guide to a Common and Complex Disease.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Joohi Jimenez-Shahed, MD Assistant Professor of Neurology Baylor College of Medicine 8 th Annual IMHO Convention April 30, 2011 – Houston, TX Parkinson’s.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
PARKINSON’S DISEASE By Courtney and Niral. WHAT IS IT?  Parkinson's disease (PD) is chronic and progressive movement disorder, meaning that symptoms.
Innovations in Parkinson’s Diagnosis & Treatment: A Personal Story Dr. Kenneth E. Keirstead Excellence in Aging Care Symposium September 25-27, 2013.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Module 3 Brain’s Building Blocks. The Human Brain 1350 gram > 3 pounds 1 trillion cells 2 types of brain cells Glial cells (900 billion) Neurons (100.
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Group 5.  100+  Precise roles not known  3 categories.
 Parkinson Disease (PD) is a disorder of the brain that causes a variety of movement problems.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
Improvement of life quality and non motor symptoms relief in patients with advanced Parkinson's disease. Natalia Prican Andra Oltean Doctor Jozsef Attila.
HOLLY CAMPBELL-BARR, LAUREN GAY AND LUCY GODDEN. The effect of drugs on the brain…
Number of neurotransmitters  Neurotransmitters are chemicals capable of transmitting a signal from the pre-synaptic to the post synaptic neurone  Over.
SYMPTOMS: Tremors, stiff muscles Shuffling gait, Poor coordination Balance problems, Fatigue Speech & swallowing difficulties TREATMENTS: Medications.
Neurological Disorders
By Katelyn Chaimson and Sean Guyot
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
The Substantia Nigra THE BRAIN Symptoms differ from every person suffering from the disease. There are two types of symptoms, primary, secondary.
 Parkinson Disease (PD) is a progressive disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
By Seamus Hogan.  Parkinsons disease is degenerative disorder of the central nervous system. it causes the dopamine to contain cells in the substantial.
Parkinson’s Disease Casey Wang
Neurotransmitters in the brain By Joon Kim. Neurotransmitters  A neurotransmitter is a specialized messenger chemical that transfers or sends information.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Neurotransmitters in the Brain. What are the different neurotransmitters in the brain? Currently, over 60 different molecules meet the criteria for being.
Parkinson Disease An Overview including Community Resources Presented by Christy Prezyna, PT Ellen Tomer, LMSW Members of HCR’s Parkinson’s Program.
Parkinson’s Disease By: Taylor Hawkins, Ana McGhee, and Morgan Zander.
Team (Phoenix) Presents Parkinson’s Disease Prepared in partial satisfaction of the requirements for GPC 126, Physiological Psychology Spring Semester,
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
PARKINSON’S DISEASE LUKE CARROLL & LAUREN DESROCHES.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Drugs Used for Parkinson’s Disease
Understanding Parkinsons Disease
Module 7.3 Movement Disorders
MOVEMENT DISORDERS.
Lecture 3 Dr.Narmin Hussen
Falon Fiorillo & Breeanna Fournier
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
WHAT I NEED TO KNOW AS A PATIENT AND A CAREGIVER
Drugs for Degenerative Diseases of the Nervous System
Management in Primary Care
Parkinson’s Disease Definitions Disease features Pathology
Conceptual diagram of dopaminergic system and disease and drug effects
Presentation transcript:

Monday 20 th July 2009 Parkinson’s Summerschool A Personal Perspective On Parkinson’s Tom Isaacs Co-Founder – Cure Parkinson’s Trust Board Member – European PD Association Steering Group – World Parkinson’s Congress

Tom’s Tiny (but tasty) Two-minute Turkey Teach-in 4 slides 30 seconds each Parkinson’s can affect anyone at age It is idiopathic – of unknown cause Increasingly it is being linked to genetics and environmental factors The shaking and immobility are caused by a deficit of dopamine in the brain Dopamine is the chemical messenger which controls movement You do not need an electric toothbrush if you have Parkinson’s

Tom’s 2-minute Turkey Teach-in. Treatment for Parkinson’s is usually with a combination of the following medications: L-dopa Agonists – patch or pill COMT Inhibitors MAOB Inhibitors Amantadine After a 2-10 years of using L-dopa-induced dyskinesia is common In later stage Parkinson’s the following further treatments are available Apomorphine – rapid response agonist by injection Duodopa – continuous dopaminergic stimulation via pump from duodenum Deep brain stimulation (DBS) – electrical implant (pacemaker for the brain) No treatment yet said to be “disease modifying” except arguably Azilect (MAOB) All Parkinson’s medicines sound like they are from an Italian restaurant menu E.g. Ropinorole, rotigotone, tolcapone, duadopa, selegeline, cabergoline, stalevo.

Tom’s 2-minute Turkey Teach-in. Current Avenues of Parkinson’s Research –Genetic profiling and biomarkers –Gene Therapy –Neurotrophic factors and neurotrophic factor inducers –Alpha–synuclein disaggregation –Calcium channels/Anti-inflammatories –Delivery Mechanisms: Viral vectors, nanotechnology, novel peptides –Stem cell therapy –Drugs for other indications e.g. Hypertension and Diabetes

Tom’s 2-minute Turkey Teach-in. COMMON SYMPTOMS INABILITY TO COMMUNICATE e.g. Parkinson’s Mask DEPRESSION BEHAVIOURAL PROBLEMS COGNITIVE ISSUES/DEMENTIA FREEZING / RIGIDITY / INABILITY TO MOVE DROOLING / DRIBBLING SEXUAL PROBLEMS – (hyper or low drive) CONSTIPATION / INCONTINENCE SPASM DYSTONIA DYSKINESIA INSOMNIA TREMOR LOSS OF SENSE OF SMELL AND TASTE DYSPHAGIA / DIFFICULTIES WITH SWALLOWING PARANOIA ON/OFF FLUCTUATIONS and lots more!!!

CARLOS

HUGO

BARRY

Monday 20 th July 2009 Parkinson’s Summerschool A Personal Perspective On Parkinson’s Tom Isaacs Co-Founder – Cure Parkinson’s Trust Board Member – European PD Association Steering Group – World Parkinson’s Congress

“The greater part of our happiness or sadness is not dependant on our circumstances but on our disposition”

PD CARE ISSUES Communication Multi-disciplinary teamwork Rigidity, inflexibility and an inability to move forward Flamboyant gestures - achieve nothing Focus Leaving it too long before next medication PD CURE ISSUES Communication Multi-disciplinary teamwork Rigidity, inflexibility and an inability to move forward Flamboyant gestures - achieve nothing Focus Leaving it too long before next medication

CARE CURE U